“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z

What happened

Vijay Pande stepped away from leading a16z’s roughly $4 billion biotech practice to launch VZVC, a leaner AI-native startup focusing on innovative biotech investments. He spoke about why biology is shifting from a discovery science toward engineering, why clinical trials remain extremely costly, and why open, shared datasets will drive AI’s true impact on medicine—not closed or proprietary data.

Why it matters

Pande’s move signals a changing investment thesis in biotech, where the emphasis is on targeted, smaller bets instead of broad portfolios. Biology becoming an engineering discipline means biotech startups need scalable, repeatable approaches rather than purely exploratory science. This raises the bar for founders who must integrate AI and data infrastructure early to survive lengthy, expensive clinical trials. Pande also challenges the sector’s reliance on exclusive datasets, arguing that open data sharing is essential to improve AI models and accelerate drug development, which could reduce costs and cut time to market.

This thinking pressures incumbents to rethink data strategies. Companies guarding clinical and biological data behind firewalls risk slowing innovation. The future of AI-driven medicine depends on collaboration and standardized data formats, putting a premium on openness and interoperability. Investors should expect a narrower focus on high-conviction bets that integrate AI fluently rather than scattershot deals.

What to watch next

Track how VZVC’s smaller-bet, AI-first approach performs in this tough biotech environment. Watch whether other investors follow Pande’s lead to prioritize open data collaborations or stick with proprietary models. Monitor early-stage startups that pair AI with biological engineering principles and standardized datasets to see if they outpace more traditional biotech ventures.

Regulators and data stewards will also be critical players as this dynamic unfolds, as their policies could accelerate or block the open data movement that Pande champions. Finally, developments in clinical trial efficiency and cost reduction tied to AI integration will be key signs of progress.

AI Quick Briefs Editorial Desk